Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis

Hang Yuan; Quanjin Dong; Bo’an Zheng; Xinye Hu; Jian-Bo Xu; Shiliang Tu

doi:10.18632/oncotarget.15425

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis

Hang Yuan, Quanjin Dong, Bo’an Zheng, Xinye Hu, Jian-Bo Xu _ and Shiliang Tu

PDF | HTML | How to cite

Oncotarget. 2017; 8:46565-46579. https://doi.org/10.18632/oncotarget.15425

Metrics: PDF 2051 views | HTML 3414 views | ?

Abstract

Hang Yuan1,2,*, Quanjin Dong1,*, Bo’an Zheng1, Xinye Hu1, Jian-Bo Xu3 and Shiliang Tu1

1 The Surgical Department of Coloproctology, Zhejiang Provincial People’s Hospital, Hangzhou, China

2 Nanjing Medical University, Nanjing, China

3 Department of Hepatobiliary Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an City, China

* These authors have contributed equally to this work

Correspondence to:

Jian-Bo Xu, email:

Shiliang Tu, email:

Keywords: lymphovascular invasion, survival, stage I/II, colorectal cancer, meta-analysis

Received: January 04, 2017 Accepted: February 08, 2017 Published: February 16, 2017

Abstract

The prognostic value of lymphovascular invasion (LVI) in stage I/II colorectal cancer (CRC) does not reach a consensus. To systematically assess prognostic significance of LVI, databases of PubMed, Web of Science, and Embase were searched from inception up to 10 Dec 2016. The pooled hazard ratio (HR) and 95% confidence intervals (CI) were used to determine the prognostic effects. Nineteen relevant studies including 9881 total patients were enrolled. Our results showed that LVI is significantly associated with poor prognosis in overall survival (OS) (HR=2.15, 95 % CI=1.72–2.68, P < 0.01) and disease-free survival (DFS) (HR=1.73, 95% CI=1.50–1.99, P < 0.01), which is similar in stage II patients. Further subgroup analysis revealed that the significance of the association between LVI and worse prognosis in CRC patients is not affected by below factors, including geographic setting, LVI positive rate, treatment, tumor site, and quality of the study. The current meta-analysis suggests that LVI may be a poor prognostic factor for stage I/II CRC patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15425

Publication Alerts

Clinical Research Papers:

Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis

Abstract